Pre-Clinical Development of Safe & Effective T Cell Receptor-Engineered CD4+ & CD8+ T Cell Therapies Specific for Mutant KRAS

Time: 10:00 am
day: Day Two


  • Advantages of TCR-engineered CD4+ and CD8+ T cell therapies to induce deep and durable anti-tumor responses against KRas mutant tumors
  • Preclinical data of TCR-engineered T cell therapies targeting KRas mutant tumors
  • Synthetic biology strategy for boosting TCR-engineered T cell trafficking and persistence in the hostile TME of KRas mutant tumors to ensure durable responses